Omeprazole delayed release
Pro Research Analysisby 
Searched over 200M research papers
Omeprazole Delayed Release: Efficacy, Formulations, and Pharmacokinetics
Introduction to Omeprazole Delayed Release
Omeprazole is a widely used proton pump inhibitor (PPI) that effectively reduces gastric acid secretion. It is commonly prescribed for conditions such as gastroesophageal reflux disease (GERD) and erosive esophagitis. Delayed-release formulations of omeprazole are designed to protect the drug from the acidic environment of the stomach, ensuring its release in the more neutral pH of the intestines.
Efficacy in Pediatric Patients
Symptom Relief and Healing Rates
Delayed-release oral suspensions of omeprazole have been shown to be highly effective in treating childhood esophagitis. Studies report a median symptom relief rate of 80.4%, with significant reductions in esophageal reflux index and intragastric acidity. Endoscopic healing rates were 84% after 8 weeks and 95% after 12 weeks of treatment, although histological healing was lower at 49% .
Pharmacokinetics and Bioavailability
Comparison with Simplified Suspension
A study comparing the pharmacokinetics of omeprazole delayed-release capsules and a simplified omeprazole suspension (SOS) found that while the SOS had a faster absorption rate, the overall bioavailability was lower compared to the capsule form. Specifically, the area under the concentration-time curve (AUC) for the SOS was significantly lower than that for the capsule, indicating reduced bioavailability .
Impact of Co-administration with Other Substances
Research has shown that the pharmacokinetics of cysteamine bitartrate delayed-release capsules are not significantly affected by co-administration with omeprazole. This suggests that omeprazole does not interfere with the absorption and efficacy of other delayed-release medications when taken together .
Formulation Innovations
Liquid Oral Dosage Forms
Recent advancements have led to the development of a liquid oral dosage form of omeprazole with delayed-release properties. This formulation uses multi-layered particles suspended in a syrup, which are coated with polymers to prevent early release in the stomach. This innovation is particularly beneficial for patients with swallowing impairments, such as pediatric, elderly, or critically ill patients. The liquid form has shown similar release performance to existing enteric-coated solid dosage forms, ensuring stability and targeted release in the intestines .
Generic Formulations
Investigations into the quality of generic omeprazole delayed-release capsules have confirmed that these generics meet the United States Pharmacopeia (USP) standards and perform similarly to the brand-name product in vitro. This addresses concerns about the therapeutic efficacy of generic versions .
Comparative Studies with Other PPIs
Immediate-Release vs. Delayed-Release
Studies comparing immediate-release omeprazole with delayed-release formulations of other PPIs, such as lansoprazole and pantoprazole, have shown that immediate-release omeprazole provides faster onset of action and better control of intragastric acidity. This is particularly evident in controlling nocturnal acid breakthrough, where immediate-release formulations have demonstrated superior efficacy 79.
Conclusion
Omeprazole delayed-release formulations are highly effective in managing conditions like GERD and esophagitis, with significant symptom relief and healing rates. Innovations in liquid dosage forms and the availability of effective generic options enhance patient compliance and accessibility. Comparative studies highlight the advantages of immediate-release formulations in specific scenarios, offering tailored treatment options for diverse patient needs.
Sources and full results
Most relevant research papers on this topic